^(89)SrCl_2联合“云克”治疗前列腺癌骨转移的临床价值  

Clinical Value of Strontium-89 Combined with ^(99)Tc-MDP in Treatment of Bone Metastases of Prostate Cancer

作　　者：朱文茹[1] 郑飞波[1] 柳炳吉[1] 戴锦朝[1] 

机构地区：[1]青岛大学医学院第二附属医院核医学科,山东青岛266042

出　　处：《标记免疫分析与临床》2011年第4期241-243,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：为探讨89SrCl2联合"云克"治疗前列腺癌多发骨转移的临床价值,将95例前列腺癌骨转移患者分为89SrCl2组(A组)46例,89SrCl2加"云克"组(B组)49例。治疗后随访患者的骨痛缓解情况、全身骨显像的变化情况以及前列腺特异抗原(PSA)变化情况。结果显示,B组患者骨痛缓解的总有效率为87.76%,骨显像完全缓解(CR)+部分缓解(PR)率为83.67%,PSA水平下降为43.8±13.5ng/mL,此三项指标均明显高于A组(P<0.05)。结论:89SrCl2联合"云克"治疗前列腺癌骨转移灶,骨痛缓解率明显提高,PSA水平明显下降,而毒副作用未见明显增加。To evaluate the clinical value of 89Sr combined with 99Tc-MD Pin treatment of multiple bone metastases of prostate cancer,95 patients with bone metastases of prostate cancer were divided into group A and group B.46 patients in group A were treated with 89Sr only,the other 49 patients in group B were treated with 89Sr combined with 99Tc-MDP.Pain palliation,the changes of bone imaging and PSA level for all patients were observed and followed up.The results showed that the total effective rate of pain palliation in group B was 87.85%,the ratio of complete relief（CR） and partial relief（PR） in bone imaging was 83.67% and the decrease of Prostate Specific Antigen（PSA） was 43.8±13.5ng/mL,which were all higher than that in group A.Conclusion The combination of 89Sr and 99Tc-MD Pin the treatment of patients with bone metastases of prostate cancer could increase rate of pain remission,decrease PSA level and not increase side-effect obviously.

关 键 词：锶-89 云克 骨转移 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤]